FASENRA 30 mg/mL
Benralizumab · INJECTION, SOLUTION · AstraZeneca Pharmaceuticals LP
Fasenra (benralizumab) is a prescription injection used to treat moderate to severe eosinophilic asthma in adults and children. It works by targeting and reducing eosinophils, a type of white blood cell involved in airway inflammation.
Key Facts
- Brand Name
- FASENRA
- Generic Name
- Benralizumab
- NDC Code (Product)
0310-1730- Manufacturer
- AstraZeneca Pharmaceuticals LP
- Strength
- 30 mg/mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761070
- Drug Class
- Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]
- Marketing Start
- 11/14/2017
Recall History
No Recall HistoryFrequently Asked Questions
What is FASENRA used for?
Fasenra (benralizumab) is a prescription injection used to treat moderate to severe eosinophilic asthma in adults and children. It works by targeting and reducing eosinophils, a type of white blood cell involved in airway inflammation.
Is FASENRA a controlled substance?
FASENRA is not classified as a controlled substance by the DEA.
What is the generic name for FASENRA?
The generic name for FASENRA is Benralizumab. There are no other listed brand versions of Benralizumab.
What is the NDC code for FASENRA 30 mg/mL?
The NDC (National Drug Code) for FASENRA 30 mg/mL is 0310-1730, listed by AstraZeneca Pharmaceuticals LP.
Other FASENRA Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)